Document Detail

Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration through p53.
MedLine Citation:
PMID:  25469035     Owner:  NLM     Status:  In-Data-Review    
AIM: To investigate the effects of 17β-estradiol via estrogen receptors (ER) or direct administration of ER agonists on human colorectal cancer.
METHODS: LoVo cells were established from the Bioresource Collection and Research Center and cultured in phenol red-free DMEM (Sigma, United States). To investigate the effects of E2 and/or ER selective agonists on cellular proliferation, LoVo colorectal cells were treated with E2 or ER-selective agonists for 24 h and 48 h and subjected to the MTT (Sigma) assay to find the concentration. And investigate the effects of E2 and/or ER selective agonists on cell used western immunoblotting to find out the diversification of signaling pathways. In order to observe motility and migration the wound healing assay and a transwell chamber (Neuro Probe) plate were tased. For a quantitative measure, we counted the number of migrating cells to the wound area post-wounding for 24 h. We further examined the cellular migration-regulating factors urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA) and matrix metalloproteinase (MMP)-9 in human LoVo cells so gelatin zymography that we used and gelatinolytic activity was visualized by Coomassie blue staining. And these results are presented as means ± SE, and statistical comparisons were made using Student's t-test.
RESULTS: The structure was first compared with E2 and ER agonists. We then treated the LoVo cells with E2 and ER agonists (10(-8) mol/L) for 24 h and 48 h and subsequently measured the cell viability using MTT assay. Our results showed that treatment with 17β-estradiol and/or ER agonists in human LoVo colorectal cancer cells activated p53 and then up-regulated p21 and p27 protein levels, subsequently inhibiting the downstream target gene, cyclin D1, which regulates cell proliferation. Taken together, our findings demonstrate the anti-tumorigenesis effects of 17β-estradiol and/or ER agonists and suggest that these compounds may prove to be a potential alternative therapy in the treatment of human colorectal cancer. These results demonstrate that 17β-estradiol and/or ER agonists downregulate migration-related proteins through the p53 signaling pathway in human LoVo colorectal cancer cells. These findings suggest that p53 plays a critical role in the 17β-estradiol and/or ER agonist-mediated protective activity against colorectal cancer progression. In addition, 17β-estradiol and/or ER agonists dramatically inhibited cell migration and reduced the expression of u-PA, t-PA and MMP-9 as well as MMP-2/9 activity in LoVo cells, which regulate cell metastasis. Moreover, we observed that pretreatment with a p53 inhibitor significantly blocked the anti-migration effects of E2 and/or ER agonists on LoVo cells. That E2 and/or ER agonists may impair LoVo cell migration by modulating migration-related factors via the p53 tumor suppressor gene.
CONCLUSION: Direct ER treatment may prove to be an attractive alternative therapy in the treatment of human colorectal tumors in the future.
Hsi-Hsien Hsu; Wei-Wen Kuo; Da-Tong Ju; Yu-Lan Yeh; Chuan-Chou Tu; Ying-Lan Tsai; Chia-Yao Shen; Sheng-Huang Chang; Li-Chin Chung; Chih-Yang Huang
Related Documents :
22332025 - The survival strategies of malaria parasite in the red blood cell and host cell polymor...
25314965 - Effect of epigenetic modification with trichostatin a and s-adenosylhomocysteine on dev...
4030245 - Adhesion and spreading characterization of a rat tumor cell system exhibiting different...
12626495 - Macroautophagy is required for multicellular development of the social amoeba dictyoste...
21715255 - Cytotoxic effects of commercial wheatgrass and fiber towards human acute promyelocytic ...
11429695 - Detection of repair activity during the dna damage-induced g2 delay in human cancer cells.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  20     ISSN:  2219-2840     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-03     Completed Date:  -     Revised Date:  2014-12-05    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  16665-73     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?
Next Document:  Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.